Vaxcyte, Inc. (NASDAQ:PCVX) is HighVista Strategies LLC’s 3rd Largest Position

HighVista Strategies LLC boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 38.2% during the third quarter, Holdings Channel reports. The firm owned 44,661 shares of the company’s stock after purchasing an additional 12,348 shares during the quarter. Vaxcyte comprises about 1.8% of HighVista Strategies LLC’s holdings, making the stock its 3rd biggest position. HighVista Strategies LLC’s holdings in Vaxcyte were worth $5,103,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PCVX. Blue Trust Inc. boosted its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Vaxcyte by 5.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock worth $252,000 after purchasing an additional 110 shares during the period. CIBC Asset Management Inc boosted its holdings in shares of Vaxcyte by 3.6% in the third quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after buying an additional 110 shares during the last quarter. Amalgamated Bank grew its position in Vaxcyte by 4.2% during the second quarter. Amalgamated Bank now owns 3,759 shares of the company’s stock valued at $284,000 after buying an additional 150 shares during the period. Finally, Riverview Trust Co purchased a new stake in Vaxcyte during the third quarter valued at approximately $27,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Down 2.9 %

NASDAQ:PCVX opened at $91.60 on Tuesday. The stock has a 50-day moving average price of $105.60 and a 200 day moving average price of $90.49. The stock has a market capitalization of $11.42 billion, a P/E ratio of -19.91 and a beta of 0.94. Vaxcyte, Inc. has a 12-month low of $52.74 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the business earned ($0.91) EPS. On average, research analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. The trade was a 31.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Grant Pickering sold 2,366 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the transaction, the chief executive officer now directly owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 87,464 shares of company stock worth $9,797,926. 3.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PCVX. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. BTIG Research lifted their target price on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Bank of America raised their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Finally, Jefferies Financial Group raised their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.